Search
for
Sort by
Research 121–150 of 1000+
- Referee report. For: Drug utilization pattern and adverse drug reactions of chemotherapy in pediatric patients at Muhimbili National Hospital, Tanzania [version 1; peer review: 1 approved, 1 approved with reservations]
- A Case Report on Recurrent Trichilemmal Carcinoma of Scalp- Role of Clinico-Radiological Correlation
- Kemoterapinin En Görünen Yönü: Alopesi: Önlemek Mümkün Mü?
- An Elevated Tumor Marker and Adrenarche in a Child Using Lavender Oil
- 2-Deoxy-2-[18F]fluoro-D-Glucose Positronen-Emissions-Tomographie/Computertomographie
- Menopause - Andropause - Anti-Aging 2008, 11.-13. Dezember 2008, Wien - Abstracts
- Slow progress in prostate cancer
- Gefitinib
- A Prepatellar Soft Tissue Mass in a 56-Year-Old Man
- Chemotherapy in Gynecologic Malignancy
- Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition
- Incidence and management of cutaneous toxicities associated with cetuximab
- Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
- Editor’s picks January 2021
- Sacituzumab Govitecan-Hziy (Trodelvy™)
- ODAC Chairs Reveal Challenges, High Drama in a Decade of Service
- PSA Test Sensitized by Finasteride
- Frozen Glove Therapy for Docetaxel-Induced Hand Problems May Not Fit All
- Used Right, IV Arsenic Is Safe & Effective
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
- Tebentafusp-tebn (Kimmtra®)
- Antibody Drug Conjugates
- A Story About Hair
- Study Answers Some Questions about Androgen Suppression Pre-Radiation, but Not All
- Lymphoma Specialists Lament the Discontinuation of Underprescribed Bexxar
- MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
- Lung Cancer Awareness Symposium Highlights Necessary Focus Areas for Research
- A Radiation Oncologist Writes
- Primary Chemoprevention Still Lacks Favor with General Physicians & Patients
- Sometimes Marketing Efforts by Advocacy Organizations Can Lose Touch with the Nuances of Appropriateness